A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Hematology
John KuruvillaArmand Keating

Abstract

Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment. We combined thalidomide (THAL), an agent with anti-angiogenic and immunomodulatory properties, with vinblastine, which is active after ASCT, to determine the objective response rate, improvement in B symptoms and toxicity in patients with refractory HD. Patients were eligible if they HD that progressed after chemotherapy and ASCT or had declined or were ineligible for curative therapy. Treatment consisted of THAL 200 mg orally given daily. After 2 weeks, VBL 6 mg IV was given weekly x 6 doses on an eight-week cycle. Response and toxicity assessment occurred following each cycle. Eleven patients were enrolled, 1 progressed within 6 days of study enrollment and was subsequently treated with alternative palliative therapy and thus 11 patients are response evaluable and 10 are evaluable for toxicity. relapsed after ASCT: 7; median number of prior chemotherapy regimens: 3 (range 1-5); median time to progression post-ASCT: 7 months (range 2-29). Four patients had a partial response to treatment (response rate 36%); two pa...Continue Reading

References

Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Aug 1, 1968·Cancer·E Z Ezdinli, L Stutzman
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Feb 25, 1993·The New England Journal of Medicine·V T DeVita, S M Hubbard
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Jul 1, 1999·Bioorganic & Medicinal Chemistry Letters·G W MullerD I Stirling
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Dec 1, 1999·Annals of the Rheumatic Diseases·L G Corral, G Kaplan
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroV Diehl
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M BaidasD F Hayes
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F BertoliniS Cineri
May 31, 2002·Blood·Brian F Skinnider, Tak W Mak
Sep 5, 2002·The Journal of Pathology·Ipatia A Doussis-AnagnostopoulouKevin C Gatter
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B DugganBruce A Peterson
Mar 17, 2004·Cancer·Barbara ProFernando Cabanillas

❮ Previous
Next ❯

Citations

Jul 17, 2013·Frontiers of Medicine·Miao XuJun Peng
Jun 10, 2008·Current Opinion in Hematology·Nancy L Bartlett
May 29, 2010·Journal of Oncology·Michael MedingerAlexandar Tzankov
Jun 25, 2014·Leukemia Research·Christian MarinaccioDomenico Ribatti
Apr 18, 2009·Leukemia & Lymphoma·Tanya M Wildes, Nancy L Bartlett
Jan 6, 2011·Expert Opinion on Investigational Drugs·Heiner AdamsAlexandar Tzankov
May 1, 2012·Blood Reviews·Jieun Uhm, John Kuruvilla
Feb 9, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Gerhard SissolakPeter Jacobs
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Rajendra Gharbaran
Mar 7, 2021·Pharmaceuticals·Paula Garcia-OliveiraMiguel Angel Prieto
Jun 30, 2019·Journal of Medicinal Chemistry·Christopher HeimMarcus D Hartmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.